Bromodomains have recently been identified as an important druggable target class in small-molecule inhibitor drug discovery yet identification and optimization of potent, highly selective small molecule bromodomain inhibitors has been limited by the absence of a comprehensive, biochemical screening platform. This presentation will provide an overview of the BROMOscan technology and detail our approach to assay development. Plus, we’ll take a look at how the technology can be applied to a variety of epigenetic targets that have important implications in a variety of diseases including inflammation, diabetes and cancer.
Free Webinar: Epigenetic Drug Discovery with Bromodomain Inhibitor Screening
Presented by Elizabeth Quinn Ph.D, DiscoverRx
Recorded on Thursday, June 21st 2012